Refractory Mantle Cell Lymphoma
Also known as: Refractory Mantle Cell Lymphoma (MCL) / Mantle Cell Lymphoma Refractory
Drug | Drug Name | Drug Description |
---|---|---|
DB06769 | Bendamustine | An antineoplastic agent used for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy. |
DB15699 | Brexucabtagene autoleucel | A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. |
DB09053 | Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
DB17472 | Pirtobrutinib | A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. |